{"id":"W2138647255","doi":"10.1016/s0140-6736(14)62113-9","title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","year":2015,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":394,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Etanercept; Tofacitinib; Placebo; Psoriasis; Internal medicine; Psoriasis Area and Severity Index; Plaque psoriasis; Janus kinase inhibitor; Population; Randomized controlled trial; Surgery; Dermatology; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002297723,0.002401658,0.004232562,0.0004429735,0.000559098,0.001914746,0.001032334,0.002686596,0.01200853],"category_scores_gemma":[0.002117051,0.0008277304,0.003718285,0.000458979,0.001265426,0.001591614,0.0005280725,0.004758311,0.00165856],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001187564,"about_ca_system_score_gemma":0.0009138623,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001388916,"about_ca_topic_score_gemma":0.002471199,"domain_scores_codex":[0.9991959,0.0003706247,0.00004933073,0.0001495209,0.00006364183,0.0001710646],"domain_scores_gemma":[0.9990087,0.0004019692,0.0001932621,0.00008785902,0.00005728797,0.0002509597],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9875402,0.001174363,0.0001815429,0.0005580051,0.001179085,0.00003711,0.00002758404,0.000191467,0.00115377,0.0001141952,0.0008275505,0.007015043],"study_design_scores_gemma":[0.9879315,0.0101117,0.0005875831,0.0000338763,0.0004304718,0.00002541276,0.00001357162,0.0001303562,0.00007886006,0.0002019909,0.0004456154,0.000008996662],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9470921,0.02730052,0.002052657,0.00382889,0.003022377,0.004436397,0.003516966,0.0003954506,0.008354691],"genre_scores_gemma":[0.9718963,0.00790394,0.001834596,0.003775415,0.001284625,0.003442465,0.001835742,0.00007964463,0.007947205],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01200853,"threshold_uncertainty_score":0.04017252,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07837364539587272,"score_gpt":0.324495817594725,"score_spread":0.2461221721988522,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}